Skip to content
logo MSD Oncology Clinical Trials
  • Home
  • Trials
    • Main Menu
    • Trial Overview
    • Bladder
    • Breast
    • Colorectal
    • Esophageal
    • Gastric
    • Gynecologic
    • Head and Neck
    • Hematologic
    • Kidney
    • Liver and Bile Duct
    • Lung
    • Melanoma
    • Pediatric
    • Prostate
    • Solid Tumors
  • About
  • Common Questions
  • For HCPs
  • English
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Therapeutic Area: Colorectal

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.

Therapeutic Area: Colorectal

Evaluation of Co-formulated Pembrolizumab/Quavonlimab Versus Other Treatments in Participants With Microsatellite Instability-High or Mismatch Repair Deficient Stage IV Colorectal Cancer

May 20, 2022

By Tyler Kalist

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.

Study of Lenvatinib in Combination With Pembrolizumab Versus Standard of Care in Participants With Metastatic Colorectal Cancer

March 7, 2022

By Tyler Kalist

The purpose of this study is to assess the safety and efficacy of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in participants with metastatic colorectal cancer. The study will also compare

Study of Pembrolizumab vs Standard Therapy in Participants With Microsatellite Instability-High or Mismatch Repair Deficient Stage IV Colorectal Carcinoma

March 7, 2022

By clique_admin

In this study, participants with stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) colorectal carcinoma (CRC) will be randomly assigned to receive either pembrolizumab or the Investigator’s choice of

Efficacy and Safety of Olaparib With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer

March 7, 2022

By clique_admin

This is an efficacy and safety study of olaparib alone or in combination with bevacizumab being compared to bevacizumab with a fluoropyrimidine in participants with unresectable or metastatic colorectal cancer who

Safety and Efficacy of Pembrolizumab Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer Participants

March 7, 2022

By Tyler Kalist

The purpose of this study is to determine safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) for the following combinations: pembrolizumab plus binimetinib (Cohort A), pembrolizumab

A Study of Coformulated Favezelimab/Pembrolizumab Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer

March 7, 2022

By clique_admin

The purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic colorectal cancer. The study will also compare MK-4280A with the standard

logo-white MSD Oncology Clinical Trials
  • MSD Privacy Policy
  • Terms of Use
  • Cookie Preferences
  • Accessibility

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

eSSENTIAL Accessibility

eSSENTIAL Accessibility